Loading…
Chinese maker of active pharmaceutical ingredients and generic formulations, a major API exporter to the US and European generics markets.
Chinese maker of active pharmaceutical ingredients and generic formulations, a major API exporter to the US and European generics markets.
Sells active ingredients to generic-drug makers worldwide, including the US and Europe, and finished generics under its own filings, so approvals by the FDA and EU regulators decide what it can ship. A 2018 impurity found in its valsartan ingredient led to recalls and regulatory action, and quality compliance has weighed on the business since.
Moat: narrow (regulatory licence, scale). FDA/EU-approved API facilities and a large ANDA portfolio, though past quality lapses have hurt trust.
Headquarters: Linhai, Zhejiang, China · Employees: 8,797
Size Zhejiang Huahai Pharmaceutical (600521.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.86B, the 664th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥17.61 on 6 Nov 2026.
Performance Over six months the shares gained 8.1%, against +2.0% for the median peer and -16.4% for the China market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue grew 10.3% over the last twelve months (peer median +3.4%); the operating margin is 12.2% (peer median 18.3%).
Valuation It trades at 22.1× forward earnings against a peer median of 19.6× (7th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.0 points above its cost of capital (6.6% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥9.60B | CN¥8.54B | CN¥9.49B | CN¥8.26B | CN¥8.23B |
| Revenue growth | — | -10% | +15% | 0% | — |
| Gross profit | CN¥6.13B | CN¥4.70B | CN¥5.50B | CN¥4.68B | CN¥4.88B |
| EBITDA | n/a | CN¥1.59B | CN¥2.49B | CN¥2.08B | CN¥2.20B |
| Net income | CN¥946M | CN¥266M | CN¥1.12B | CN¥830M | CN¥1.17B |
| Free cash flow | CN¥249M | -CN¥734M | CN¥320M | CN¥630M | -CN¥1.07B |
| Capital expenditure | CN¥1.86B | CN¥1.97B | CN¥1.85B | CN¥1.59B | CN¥2.32B |
| Total debt | CN¥8.94B | CN¥8.66B | CN¥8.07B | CN¥7.45B | CN¥7.42B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhejiang Huahai Pharmaceutical 600521.SS | $3.86B | +8% | +10% | 12% | 22.1× | 7.3% |
| Apeloa Pharmaceutical 000739.SZ | $3.73B | +18% | -16% | 10% | 25.1× | 6.3% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | $2.12B | +17% | -1% | 14% | 17.5× | 2.4% |
| Zhejiang Hisun Pharmaceutical 600267.SS | $2.32B | +18% | -7% | 15% | 17.0× | -9.1% |
| Zhejiang Xianju Pharmaceutical 002332.SZ | $1.34B | +2% | +8% | 11% | 18.6× | 0.3% |
| Zhejiang Medicine 600216.SS | $1.61B | -23% | -6% | 7% | 11.3× | -6.7% |
| Aurobindo Pharma AUROPHARMA.NS | $10.9B | +22% | +14% | 15% | 22.4× | 21.0% |
| Dr. Reddy's Laboratories DRREDDY.NS | $12.1B | +5% | -4% | 9% | 31.8× | 30.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600521.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.8% | +6.2% | 10th lowest of 21 |
| 6-month return | +8.1% | +2.0% | 5th highest of 20 |
| Distance from 52-week high | -9.4% | -23.8% | 4th highest of 21 |
| Revenue growth (TTM) | +10.3% | +3.4% | 7th highest of 19 |
| Operating margin | 12.2% | 18.3% | 6th lowest of 17 |
| Forward P/E | 22.1× | 19.6× | 7th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 7.3% | -0.8% | 5th most demanding of 15 |
| Growth delivered (Del g) | +5.9% | +7.0% | 7th lowest of 15 |
| Hurdle (Req g minus delivered) | +1.4 pp | -11.2 pp | 4th most demanding of 15 |
| ROIC minus cost of capital | +2.0 pp | +8.0 pp | 5th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.86B | +8% | +10% | 12% | 22.1× | 7.3% | +5.9% |
| Santen Pharmaceutical 4536.T | Japan | $3.86B | +17% | -1% | 16% | 15.6× | -5.2% | +3.2% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.89B | +15% | +3% | 20% | 22.3× | 1.5% | +12.1% |
| Xenon Pharmaceuticals XENE | United States | $3.79B | +4% | -100% | n/a | n/a | n/a | n/a |
| Liquidia LQDA | United States | $3.97B | +5% | +2,234% | 37% | 32.9× | 0.7% | +192.5% |
| Siegfried SFZN.SW | Switzerland | $3.98B | -10% | +4% | 16% | 17.8× | n/a | n/a |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.74B | -11% | +8% | 4% | 6.0× | -5.3% | +7.8% |
| Apeloa Pharmaceutical 000739.SZ | China | $3.73B | +18% | -16% | 10% | 25.1× | 6.3% | +4.5% |
| Livzon Pharmaceutical 000513.SZ | China | $3.71B | -4% | -14% | 19% | 16.9× | -9.8% | +2.7% |
| Amylyx Pharmaceuticals AMLX | United States | $3.70B | +97% | +100% | n/a | n/a | n/a | n/a |
| Yuhan 000100.KS | South Korea | $4.05B | -12% | +5% | 5% | 38.6× | 20.2% | +6.2% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.05B | +6% | -4% | 32% | 14.9× | -11.5% | +0.3% |
| Shanghai Junshi Biosciences 688180.SS | China | $4.06B | -24% | +29% | -15% | n/a | n/a | n/a |
| ACADIA Pharmaceuticals ACAD | United States | $3.66B | -5% | +12% | 8% | 21.5× | 16.7% | +19.4% |
| Organon & OGN | United States | $3.64B | +4% | -3% | 20% | 4.0× | -4.5% | -1.0% |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.63B | -7% | +27% | 18% | 14.3× | -2.8% | +10.6% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $4.11B | +4% | -13% | 20% | 31.4× | 17.8% | -5.8% |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.60B | -13% | +136% | 29% | 43.4× | 20.5% | +98.4% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.47B | +2% | +3% | 19% | 19.6× | -2.2% | +12.0% |
| Viking Therapeutics VKTX | United States | $3.42B | -17% | n/a | n/a | n/a | n/a | n/a |